Skip to main content

Medical Marijuana, Inc. Announces Sales Operations Milestone; Sells More Than 1.6 Billion Milligrams of CBD

Written by Customer Service on . Posted in Public Companies.

SAN DIEGO, Aug. 27, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company has reached a significant operational milestone of selling and shipping more than 1.6 billion milligrams of hemp-based cannabidiol (CBD) since 2017.
The Company’s milestone comes at a time when e-commerce CBD sales have seen a sharp increase as four out of 10 CBD consumers plan to use CBD oil more frequently during the COVID-19 pandemic and 15 percent of those consumers plan on using a higher dose of CBD than usual. “For a decade, our Company has offered the highest potency CBD product in an oral applicator form through our flagship product, Real Scientific Hemp Oil™. We’ve seen international media coverage of our customers having positive experiences with our products for over half of a decade,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Many products on the market today use isolate forms of CBD, or contain no CBD at all, marketing themselves as ‘hemp oil.’ While we are glad to have such high demand for CBD products, we’re also proud to remain one of the highest quality CBD oils on the market.”As one of the pioneers of the American hemp CBD industry, Medical Marijuana, Inc. has advocated for the compound for over a decade and the Company’s products have remained popular among consumers as mass awareness of CBD rapidly increases. Today, over 62 percent of Americans recognize CBD and/or CBD products and about 33 percent of Americans have used CBD at least once.“We continue to believe in a world where CBD and other cannabinoid-based products are a part of the general population’s everyday wellness routine,” said Medical Marijuana, Inc. COO Blake Schroeder. “While many new companies enter the hemp CBD space, our portfolio of companies was the first to legally offer CBD products derived from industrial hemp.”For more information on the Company, please visit www.medicalmarijuanainc.com.About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSUREThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.LEGAL DISCLOSUREMedical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.CONTACT:Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 858-264-6600
andrew.hard@cmwmedia.com
www.cmwmedia.comInvestor Relations Contact:
P. (858) 283-4016
Investors@medicalmarijuanainc.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.